Hepatitis C virus genotype 1
Drug research and approvals for hepatitis C virus genotype 1: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 0 studies of hepatitis C virus genotype 1 are recruiting on ClinicalTrials.gov, Health Canada has authorized 20 drug trials for it since 2013, and FDA has 1 approved and 0 open orphan designations naming it.
- Recruiting worldwide: 0
- Trials authorized in Canada: 20
- FDA orphan approvals: 1
- EU medicines: 0
| Oct 22, 2015 | An open-label, multicenter study to evaluate the pharmacokinetics, safety, and efficacy of ombitasvir (OBV), paritaprevir (PTV), ritonavir (RTV) with or…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/… | AbbVie | Pending |
| Sep 30, 2015 | An open-label, single arm study to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir in treatment-naïve adults with genotype…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333) | AbbVie | Closed |
| Sep 29, 2015 | The effects of anti-viral therapy on the clinical status, quality of life, and survival of patients with decompensated cirrhosis due to hepatitis C genotype 1…Ledipasvir-sofosbuvir | Toronto General Hospital | Closed |
| Jul 10, 2015 | Open-label study to evaluate the safety and efficacy of the combination of ombitasvir, paritaprevir/r ± dasabuvir with ribavirin (RBV) in adult patients with…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/… | AbbVie | Closed |
| Feb 4, 2015 | A phase 2, open-label study to investigate the efficacy, safety, tolerability and pharmacokinetics of 6 or 8 weeks of treatment with simeprevir, daclatasvir…Simeprevir / Sofosbuvir/ Daclatasvir | Johnson & Johnson | Closed |
| Dec 18, 2014 | A phase II, randomized, open-label clinical trial to study the efficacy and safety of the combination regimen of MK-5172 and MK-3682 with either MK-8742 or…MK-3682/ MK-5172/ MK-8742/ MK-8408 | Merck & Co. (MSD) | Closed |
| Sep 24, 2014 | An open-label, multicenter study to evaluate long-term outcomes with ABT-450/ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 with or without ribavirin (RBV)…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/… | AbbVie | Ongoing |
| Aug 26, 2014 | An open-label, single-arm study to evaluate the safety and efficacy of ombitasvir/ABT-450/ ritonavir and dasabuvir in adults with genotype 1b chronic hepatitis…ABT-450-ritonavir-ABT-267/ Dasabuvir | AbbVie | Closed |
| Aug 13, 2014 | An open-label study to evaluate the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin in adults with genotype 1 and…Paritaprevir (ABT-450)-ritonavir-ombitasvir (ABT-267)/ Dasabuvir (ABT-333)/… | AbbVie | Closed |
| Jul 23, 2014 | A multicenter, open-label, partially randomized, parallel-group, adaptive design, phase II study on efficacy and safety of DEB025/alisporivir in combination…Alisporivir (DEB025)/ Mericitabine (RO5024048)/ Ribavirin | Novartis Pharmaceuticals | Pending |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Apr 7, 2017 | HarvoniTreatment of pediatric patients 12 years of age and older or weighing at least 35 kg with chronic hepatitis C virus genotype 1, 4, 5, or 6… | Gilead Sciences, Inc. | Approved |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA